Clinical Study
Design of the Tocilizumab in Giant Cell Arteritis Trial
Table 3
Standardized prednisone-taper protocols during GiACTA.
| Weeks | Daily prednisone dose (mg) 26-week taper | Daily prednisone dose (mg) 52-week taper |
| 1 | 60 | 60 | 2 | 50 | 50 | 3 | 40 | 40 | 4 | 35 | 35 | 5 | 30 | 30 | 6 | 25 | 25 | 7 | 20 | 20 |
| After week 7, the CS dosing will be double-blinded |
| 8 | 15 | 17.5 | 9 | 12.5 | 17.5 | 10 | 12.5 | 15 | 11 | 10 | 15 | 12 | 9 | 12.5 | 13 | 8 | 10 | 14 | 7 | 10 | 15 | 6 | 10 | 16 | 6 | 10 | 17 | 5 | 9 | 18 | 5 | 9 | 19 | 4 | 9 | 20 | 4 | 9 | 21 | 3 | 8 | 22 | 3 | 8 | 23 | 2 | 8 | 24 | 2 | 8 | 25 | 1 | 7 | 26 | 1 | 7 | 27 | CS placebo | 7 | 28 | CS placebo | 7 | 29 | CS placebo | 6 | 30 | CS placebo | 6 | 31 | CS placebo | 6 | 32 | CS placebo | 6 | 33 | CS placebo | 5 | 34 | CS placebo | 5 | 35 | CS placebo | 5 | 36 | CS placebo | 5 | 37 | CS placebo | 4 | 38 | CS placebo | 4 | 39 | CS placebo | 4 | 40 | CS placebo | 4 | 41 | CS placebo | 3 | 42 | CS placebo | 3 | 43 | CS placebo | 3 | 44 | CS placebo | 3 | 45 | CS placebo | 2 | 46 | CS placebo | 2 | 47 | CS placebo | 2 | 48 | CS placebo | 2 | 49 | CS placebo | 1 | 50 | CS placebo | 1 | 51 | CS placebo | 1 | 52 | CS placebo | 1 |
|
|